Bristol Myers Squibb (BMY) Non Operating Income (2009 - 2026)

Bristol Myers Squibb has disclosed Non Operating Income across 18 years of filings, most recently posting -$32.0 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 90.56% year-over-year to -$32.0 million; the TTM figure through Mar 2026 stood at -$367.0 million (up 68.11% YoY), while the FY2025 annual figure was -$674.0 million, up 24.52% from the prior year.
• Non Operating Income retreated to -$32.0 million in Q1 2026, from $51.0 million in the prior quarter.
• Over the last five years, Non Operating Income for BMY reached as high as $413.0 million in Q1 2023 and fell as low as -$649.0 million in Q1 2022.
• The 5-year median for Non Operating Income is -$32.0 million (2026), against an average of -$59.8 million.
• Annual changes were most pronounced in 2022 — Non Operating Income slumped 14300.0% — and 2023, when it surged 163.64%.
• A 5-year view of Non Operating Income shows it stood at $217.0 million in 2022, then soared by 70.97% to $371.0 million in 2023, then tumbled by 182.21% to -$305.0 million in 2024, then soared by 116.72% to $51.0 million in 2025, then sank by 162.75% to -$32.0 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered -$32.0 million, $51.0 million, and $108.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.